Recent study discovered that the combination therapy of glycolytic inhibitor 2-deoxy-D-Glucose and Rad51 specific inhibitor has shown increased efficacy for targeting leukemias, indicating increasing the efficacy of glycolytic blockade in tumor cells via Rad51 inhibition (34). The gene discussed is RAD51; the disease is neoplasm.